Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.
-
The data show that mesutoclax demonstrates outstanding efficacy and safety in treating various hematologic malignancies.
-
InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.
-
The first patient has been dosed in the registrational trial of InnoCare's BCL2 inhibitor mesutoclax for patients with BTK inhibitor treated MCL in China.